المؤلفون: Wenmin Chen, Lingqian Zheng, Jiali Wang, Yongda Lin, Tianbiao Zhou

المصدر: Frontiers in Endocrinology, Vol 14 (2023)

مصطلحات موضوعية: finerenone, chronic kidney disease, type 2 diabetes, diabetic kidney disease, cardiovascular disease, non-steroidal mineralocorticoid receptor antagonist, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: Diabetic kidney disease (DKD) is a common disorder with numerous severe clinical implications. Due to a high level of fibrosis and inflammation that contributes to renal and cardiovascular disease (CVD), existing treatments have not effectively mitigated residual risk for patients with DKD. Excess activation of mineralocorticoid receptors (MRs) plays a significant role in the progression of renal and CVD, mostly by stimulating fibrosis and inflammation. However, the application of traditional steroidal MR antagonists (MRAs) to DKD has been limited by adverse events. Finerenone (FIN), a third-generation non-steroidal selective MRA, has revealed anti-fibrotic and anti-inflammatory effects in pre-clinical studies. Current clinical trials, such as FIDELIO-DKD and FIGARO-DKD and their combined analysis FIDELITY, have elucidated that FIN reduces the kidney and CV composite outcomes and risk of hyperkalemia compared to traditional steroidal MRAs in patients with DKD. As a result, FIN should be regarded as one of the mainstays of treatment for patients with DKD. In this review, the safety, efficiency, and potential mechanisms of FIN treatment on the renal system in patients with DKD is reviewed.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fendo.2023.1320603/fullTest; https://doaj.org/toc/1664-2392Test

الوصول الحر: https://doaj.org/article/dba4b908b7cf47e58d704b9bd4c07282Test

المؤلفون: Yipin Liu, Kai Hong, Wenjuan Weng, Shuangyi Huang, Tianbiao Zhou

المصدر: Libyan Journal of Medicine, Vol 18, Iss 1 (2023)

مصطلحات موضوعية: Chronic kidney disease (CKD), vascular endothelial growth factor (VEGF), +936C/T, gene polymorphism, meta-analysis, Medicine

الوصف: ABSTRACT Vascular endothelial growth factor (VEGF) is a heparin-specific growth factor specific for vascular endothelial cells and induces angiogenesis via binding to vascular endothelial growth factor receptor (VEGFR). Chronic kidney disease (CKD), accompanied by microvascular disease, is recognized as an irreversible reduction of renal function. The effects of VEGF on CKD risk were evaluated in this study. 121 CKD patients and 50 healthy volunteers were evaluated in the current study. Data mining using the China Biological Medicine (CBM) and NCBI/PubMed databases, was performed and applicable investigations were pursued. Pooled mean differences (MD) and pooled odds ratios (OR), with corresponding confidence intervals (CIs), were calculated by meta-analysis. The levels of Scr, BUN and VEGF in the CKD group were significantly higher, when compared with the control group (P

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1993-2820Test; https://doaj.org/toc/1819-6357Test

الوصول الحر: https://doaj.org/article/201f0b6864184d78a47aebd2dd50e156Test

المؤلفون: Xiutian Chen, Jiali Wang, Yongda Lin, Kaijin Yao, Yina Xie, Tianbiao Zhou

المصدر: Frontiers in Endocrinology, Vol 14 (2023)

مصطلحات موضوعية: sodium-glucose cotransporter 2(SGLT2) inhibitors, chronic kidney disease (CKD), randomized controlled trial (RCT), meta-analysis, cardiovascular, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: BackgroundSodium–glucose co-transporter 2 (SGLT2) inhibitors provide cardiovascular protection for patients with heart failure (HF) and type 2 diabetes mellitus (T2DM). However, there is little evidence of their application in patients with chronic kidney disease (CKD). Furthermore, there are inconsistent results from studies on their uses. Therefore, to explore the cardiovascular protective effect of SGLT2 inhibitors in the CKD patient population, we conducted a systematic review and meta-analysis to evaluate the cardiovascular effectiveness and safety of SGLT2 inhibitors in this patient population.MethodWe searched the PubMed® (National Library of Medicine, Bethesda, MD, USA) and Web of Science™ (Clarivate™, Philadelphia, PA, USA) databases for randomized controlled trials (RCTs) of SGLT2 inhibitors in CKD patients and built the database starting in January 2023. In accordance with our inclusion and exclusion criteria, the literature was screened, the quality of the literature was evaluated, and the data were extracted. RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) and Stata® 17.0 (StataCorp LP, College Station, TX, USA) were used for the statistical analyses. Hazard ratios (HRs), odds ratios (ORs), and corresponding 95% confidence intervals (CIs) were used for the analysis of the outcome indicators.ResultsThirteen RCTs were included. In CKD patients, SGLT2 inhibitors reduced the risk of cardiovascular death (CVD) or hospitalization for heart failure (HHF) by 28%, CVD by 16%. and HHF by 35%. They also reduced the risk of all-cause death by 14% without increasing the risk of serious adverse effects (SAEs) and urinary tract infections (UTIs). However, they increased the risk of reproductive tract infections (RTIs).ConclusionSGLT2 inhibitors have a cardiovascular protective effect on patients with CKD, which in turn can significantly reduce the risk of CVD, HHF, and all-cause death without increasing the risk of SAEs and UTIs but increasing the risk of RTIs.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fendo.2023.1236404/fullTest; https://doaj.org/toc/1664-2392Test

الوصول الحر: https://doaj.org/article/5907c12653bb469682166266743f86a5Test

المؤلفون: Kaijin Yao, Yina Xie, Jiali Wang, Yongda Lin, Xiutian Chen, Tianbiao Zhou

المصدر: Frontiers in Immunology, Vol 14 (2023)

مصطلحات موضوعية: systemic lupus erythematosus, gut microbiota, dysbiosis, immune dysregulation, cytokines, Immunologic diseases. Allergy, RC581-607

الوصف: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age and is characterized by the damage to multiple target organs. The pathogenesis of SLE is complex, and its etiology mainly involves genetic and environmental factors. At present, there is still a lack of effective means to cure SLE. In recent years, growing evidence has shown that gut microbiota, as an environmental factor, triggers autoimmunity through potential mechanisms including translocation and molecular mimicry, leads to immune dysregulation, and contributes to the development of SLE. Dietary intervention, drug therapy, probiotics supplement, fecal microbiome transplantation and other ways to modulate gut microbiota appear to be a potential treatment for SLE. In this review, the dysbiosis of gut microbiota in SLE, potential mechanisms linking gut microbiota and SLE, and immune dysregulation associated with gut microbiota in SLE are summarized.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1202850/fullTest; https://doaj.org/toc/1664-3224Test

الوصول الحر: https://doaj.org/article/6f84d0355f7d4be5a4cfe342a3edfc04Test

المؤلفون: Jiali Wang, Shujun Lin, Hong-Yan Li, Wenzhuang Tang, Yiping Liu, Tianbiao Zhou

المصدر: Frontiers in Public Health, Vol 10 (2022)

مصطلحات موضوعية: magnesium, chronic kidney disease, hemodialysis (HD), peritoneal dialysis (PD), multicenter study, Public aspects of medicine, RA1-1270

الوصف: IntroductionMagnesium (Mg) disturbances are related to cardiac, bone, and renal patient mortality. In this study, we compared biochemical markers in hemodialysis (HD) and peritoneal dialysis (PD) patients and explored the influencing factors of serum Mg in stage 5 chronic kidney disease (CKD5) patients.Material and methodsAll 598 patients with CKD5 from three medical centers in South China were recruited into this prospective cohort study from March 1, 2018, to January 31, 2021. Our study recorded the clinical characteristics and laboratory data of the patients.ResultsHemodialysis patients (0.99 ± 0.19 mmol/L) had a higher mean serum Mg level than PD patients (0.86 ± 0.20 mmol/L; p < 0.01). Regression analysis showed that only corrected calcium (Ca), phosphate (P), Ca/Mg, Ca × P, albumin (Alb), total protein and creatine (Cr) predicted Mg levels in CKD5 patients (p < 0.01). Ca/Mg predicts hypomagnesemia with 78% sensitivity and 85% specificity in CKD5 patients. The AUC value corresponding to Ca/Mg was 0.88.ConclusionsThis multicenter study in southern China showed that for all CKD5 patients, corrected Ca and Alb had a significant positive effect on serum Mg, while Ca/Mg had a significant negative effect on serum Mg. In 123 HD patients, Ca × P was positively associated with Mg while Ca/Mg and P were negatively associated with Mg. In 398 PD patients, Ca × P, Alb, and total protein were positively associated with Mg while Ca/Mg and P were negatively associated with Mg. In 77 non-dialysis patients, corrected Ca, Cr, and total protein were positively associated with Mg while Ca/Mg was negatively associated with Mg. Furthermore, Ca/Mg might be another useful technique to monitor blood Mg levels in CKD5 patients.Clinical trial registrationChiCTR1800014557.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fpubh.2022.1047602/fullTest; https://doaj.org/toc/2296-2565Test

الوصول الحر: https://doaj.org/article/0adf800511194d809c6202707ba1cbbdTest

المؤلفون: Jiali Wang, Yongda Lin, Xiutian Chen, Yiping Liu, Tianbiao Zhou

المصدر: Frontiers in Cell and Developmental Biology, Vol 10 (2022)

مصطلحات موضوعية: mesenchymal stem cells, mesenchymal stem cell-derived extracellular vesicles, chronic kidney disease, diabetic nephropathy, lupus nephritis, autosomal dominant polycystic kidney disease, Biology (General), QH301-705.5

الوصف: Chronic kidney disease (CKD) has a major impact on public health, which could progress to end-stage kidney disease (ESRD) and consume many medical resources. Currently, the treatment for CKD has many flaws, so more effective treatment tools are urgently required for CKD. Mesenchymal stem cells (MSCs) are primitive cells with self-renewal and proliferation capacity and differentiation potential. Extensive preclinical and clinical data has shown that cell-based therapies using MSCs can modulate immunity, inhibit inflammatory factors, and improve renal function in CKD, suggesting that MSCs have the potential to be a new, effective therapeutic tool for CKD. In this review, we will describe different kinds of MSCs and MSCs products for the treatment of CKD in experimental models and clinical trials, potential signaling pathways, therapeutic efficacy, and critical issues that need to be addressed before therapeutic application in humans.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fcell.2022.910592/fullTest; https://doaj.org/toc/2296-634XTest

الوصول الحر: https://doaj.org/article/ee5b351e3a0c48c49a28a58d34d8416fTest

المؤلفون: Yiping Liu, Yan-Yan Su, Qian Yang, Tianbiao Zhou

المصدر: Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-18 (2021)

مصطلحات موضوعية: Stem cells, Renal fibrosis, Signaling pathway, Macrophages, Medicine (General), R5-920, Biochemistry, QD415-436

الوصف: Abstract Renal fibrosis commonly leads to glomerulosclerosis and renal interstitial fibrosis and the main pathological basis involves tubular atrophy and the abnormal increase and excessive deposition of extracellular matrix (ECM). Renal fibrosis can progress to chronic kidney disease. Stem cells have multilineage differentiation potential under appropriate conditions and are easy to obtain. At present, there have been some studies showing that stem cells can alleviate the accumulation of ECM and renal fibrosis. However, the sources of stem cells and the types of renal fibrosis or renal fibrosis models used in these studies have differed. In this review, we summarize the pathogenesis (including signaling pathways) of renal fibrosis, and the effect of stem cell therapy on renal fibrosis as described in preclinical and clinical studies. We found that stem cells from various sources have certain effects on improving renal function and alleviating renal fibrosis. However, additional clinical studies should be conducted to confirm this conclusion in the future.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1757-6512Test

الوصول الحر: https://doaj.org/article/1e046a279a844977a14b87a008746334Test

المؤلفون: Yongda Lin, Qian Yang, Jiali Wang, Xiutian Chen, Yiping Liu, Tianbiao Zhou

المصدر: Frontiers in Endocrinology, Vol 13 (2022)

مصطلحات موضوعية: diabetic kidney disease, mesenchymal stem cells, extracellular vesicles, signaling pathway, end-stage renal disease, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: Diabetic kidney disease (DKD) is one of complications of diabetes mellitus with severe microvascular lesion and the most common cause of end-stage chronic kidney disease (ESRD). Controlling serum glucose remains the primary approach to preventing and slowing the progression of DKD. Despite considerable efforts to control diabetes, people with diabetes develop not only DKD but also ESRD. The pathogenesis of DKD is very complex, and current studies indicate that mesenchymal stromal cells (MSCs) regulate complex disease processes by promoting pro-regenerative mechanisms and inhibiting multiple pathogenic pathways. Extracellular vesicles (EVs) are products of MSCs. Current data indicate that MSC-EVs-based interventions not only protect renal cells, including renal tubular epithelial cells, podocytes and mesangial cells, but also improve renal function and reduce damage in diabetic animals. As an increasing number of clinical studies have confirmed, MSC-EVs may be an effective way to treat DKD. This review explores the potential efficacy and signaling pathways of MSC-EVs in the treatment of DKD.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fendo.2022.962635/fullTest; https://doaj.org/toc/1664-2392Test

الوصول الحر: https://doaj.org/article/4b57fe7773804ba0bf106ffefb665c14Test

المؤلفون: Chunling Liao, Guangyong Chen, Qian Yang, Yiping Liu, Tianbiao Zhou

المصدر: Frontiers in Cell and Developmental Biology, Vol 10 (2022)

مصطلحات موضوعية: chronic kidney disease, renal fibrosis, mesenchymal stromal/stem cells, extracellular vesicles, acute kidney injury, Biology (General), QH301-705.5

الوصف: Renal fibrosis (RF) is central pathological pathway for kidney diseases, with the main pathological features being the aberrant accumulation of myofibroblasts that produce accumulation of extracellular matrix in the renal interstitium and glomeruli. Acute kidney injury (AKI) and chronic kidney disease (CKD) are associated with RF. Current treatment strategies for RF are ineffective. Mesenchymal stem cells (MSCs) have been found to be able to treat organ fibrosis including RF, but they have some safety problems, such as cell rejection, carcinogenicity, and virus contamination, which limit the application of MSCs. However, current studies have found that MSCs may exert their therapeutic effect by releasing extracellular vesicles (EVs). MSC-EVs can transfer functional proteins and genetic material directly to the recipient cells. As non-cell membrane structures, MSC-EVs have the advantages of low immunogenicity, easy preservation, and artificial modification, but do not have the characteristics of self-replication and ectopic differentiation. Therefore, EVs are safer than MSCs for treatment, but might be less effective than MSCs. Recent studies have also found that MSC-EVs can improve renal function and pathological changes of RF. Thus, this review summarizes the therapeutic effect of MSC-EVs on RF and the mechanisms that have been discovered so far, so as to provide a theoretical basis for the further study of the role of MSC-EVs in treating RF diseases.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fcell.2022.824752/fullTest; https://doaj.org/toc/2296-634XTest

الوصول الحر: https://doaj.org/article/4130efe71a8f4430a8a371fc52a4c340Test

المؤلفون: Wenshan Lin, Hong-Yan Li, Qian Yang, Guangyong Chen, Shujun Lin, Chunling Liao, Tianbiao Zhou

المصدر: Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-21 (2021)

مصطلحات موضوعية: Mesenchymal stem cell, Diabetic kidney disease, Animal study, Clinical trial, Meta-analysis, Systematic review, Medicine (General), R5-920, Biochemistry, QD415-436

الوصف: Abstract Background Mesenchymal stem cell (MSC) therapy shows great promise for diabetic kidney disease (DKD) patients. Research has been carried out on this topic in recent years. The main goals of this paper are to evaluate the therapeutic effects of MSCs on DKD through a meta-analysis and address the mechanism through a systematic review of the literature. Method An electronic search of the Embase, Cochrane Library, ISI Web of Science, PubMed, and US National Library of Medicine (NLM) databases was performed for all articles about MSC therapy for DKD, without species limitations, up to January 2020. Data were pooled for analysis with Stata SE 12. Result The MSC-treated group showed a large and statistically significant hypoglycemic effect at 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, and 6 months. Total hypoglycemic effect was observed (SMD = − 1.954, 95%CI − 2.389 to − 1.519, p

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1757-6512Test

الوصول الحر: https://doaj.org/article/a3de4671058447b1b0b92e1184d7167fTest